|
|
|
|
|||||
|
|
|
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC Capital Markets Global Healthcare Conference, taking place in New York on May 20-21, 2025.
| RBC Capital Markets Global Healthcare Conference | |
| Date: | Wednesday, May 21, 2025 |
| Time: | 3:05p.m. EDT |
| Format: | Fireside Chat |
| Webcast: | Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576
| May-23 | |
| May-23 | |
| May-21 | |
| May-20 | |
| May-15 | |
| May-10 | |
| May-09 | |
| May-09 | |
| May-06 | |
| May-06 | |
| May-05 | |
| Apr-29 | |
| Apr-09 | |
| Apr-09 | |
| Apr-08 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite